Cardiac Diabetic Tablets

Cardiac Diabetic Tablets — Saturn Formulations PCD Pharma Franchise

India faces a dual epidemic of cardiovascular disease and diabetes mellitus that is among the most significant public health challenges of the twenty-first century. With over 77 million diabetics and an estimated 54 million individuals with cardiovascular disease, India represents one of the largest markets for cardiac and diabetic medications in the world. Saturn Formulations, a WHO-GMP and ISO-certified pharmaceutical manufacturer established in 2012, offers a comprehensive range of Cardiac Diabetic Tablets addressing hypertension management, dyslipidaemia, type-2 diabetes mellitus, coronary artery disease, and associated comorbidities — making it the ideal portfolio for PCD Pharma Franchise partners targeting cardiologists, diabetologists, internists, and general physicians.

Our cardiac-diabetic tablet formulations are developed with pharmacokinetic precision — ensuring that antihypertensives achieve controlled plasma level profiles, statins are formulated at optimal pH for absorption, and antidiabetic agents maintain bioavailability through the GI transit. Every product is manufactured in our DCGI-approved facility with full Schedule H compliance documentation.

Why Choose Saturn Formulations for Cardiac Diabetic Tablet Franchise?

• Chronic Disease Market: Hypertension and diabetes are lifelong conditions requiring daily medication — generating monthly repeat prescriptions and highly predictable franchise revenue.
• Comprehensive Therapeutic Coverage: ACE inhibitors, ARBs, beta-blockers, calcium channel blockers, statins, metformin, sulfonylureas, DPP-4 inhibitors, and SGLT-2 inhibitors all available under one franchise.
• Fixed-Dose Combinations (FDCs): High-value combination tablets (Metformin + Glimepiride, Amlodipine + Atorvastatin, Telmisartan + Amlodipine) command premium MRPs and are actively prescribed by specialists.
• WHO-GMP and DCGI Compliance: Full regulatory assurance for Schedule H cardiac and antidiabetic products.
• Specialist Detailing Support: Cardiology and diabetology-specific promotional literature, slide kits, and patient education materials provided.
• Monopoly Territory Rights: Exclusive district-wise assignment for maximum market protection.

Our Cardiac Diabetic Tablet Range

Antihypertensive Tablets

Telmisartan 20mg, 40mg, 80mg; Losartan 25mg, 50mg; Amlodipine 2.5mg, 5mg, 10mg; Ramipril 1.25mg, 2.5mg, 5mg, 10mg; Metoprolol Succinate 25mg, 50mg ER; Atenolol 25mg, 50mg, 100mg; Furosemide 20mg, 40mg. All available in standard and combination variants.

Fixed-Dose Antihypertensive Combinations

Telmisartan + Amlodipine, Telmisartan + Chlorthalidone, Losartan + Hydrochlorothiazide, Amlodipine + Atorvastatin — among the most prescribed combination antihypertensives in cardiology and internal medicine practice.

Antidiabetic Tablets

Metformin 500mg, 850mg, 1000mg IR and SR tablets; Glimepiride 1mg, 2mg, 3mg, 4mg; Sitagliptin 25mg, 50mg, 100mg; Voglibose 0.2mg, 0.3mg; Dapagliflozin 5mg, 10mg; Empagliflozin 10mg, 25mg. These span all major antidiabetic drug classes for comprehensive portfolio coverage.

Antidiabetic Fixed-Dose Combinations

Metformin + Glimepiride, Metformin + Sitagliptin, Metformin + Voglibose, Metformin + Dapagliflozin — high-prescription FDCs for simplified diabetes management. These combination products represent the fastest-growing segment of the antidiabetic market.

Statin and Dyslipidaemia Tablets

Atorvastatin 5mg, 10mg, 20mg, 40mg, 80mg; Rosuvastatin 5mg, 10mg, 20mg, 40mg; Fenofibrate 145mg, 160mg; Ezetimibe 10mg — individually and as combinations (Rosuvastatin + Ezetimibe, Atorvastatin + Fenofibrate) for comprehensive dyslipidaemia management.

Quality Assurance — Cardiac Diabetic Manufacturing

Cardiac and antidiabetic medications are taken daily, often for life — making consistent potency and bioavailability non-negotiable from both a clinical safety and regulatory perspective. Saturn Formulations subjects every cardiac-diabetic tablet to HPLC content assay, dissolution profiling per USP/IP specifications, content uniformity testing, and ICH Q1A(R2) accelerated stability studies.

Extended-release and sustained-release cardiac formulations (Metoprolol Succinate ER, Metformin SR) undergo rigorous multi-timepoint dissolution testing to confirm controlled drug release profiles that match the innovator product specifications. Our QA team maintains full batch traceability from raw material receipt to finished product dispatch.

Business Case — Cardiac Diabetic Franchise

The cardiac-diabetic pharmaceutical segment is India's single largest therapeutic category by value, exceeding INR 25,000 crore annually. Unlike acute-condition medications, cardiac and diabetic drugs generate mandatory monthly repeat prescriptions — creating a revenue annuity for franchise partners rather than episodic sales. Patient loyalty to a prescribed brand is high in chronic disease management, meaning that once a prescriber adopts a Saturn Formulations cardiac-diabetic product, repeat business is virtually guaranteed.

The introduction of SGLT-2 inhibitors and DPP-4 inhibitors into India's antidiabetic market has opened a premium pricing tier within the franchise portfolio — these newer-class drugs command significantly higher MRPs and cardiologist-level prescribing, delivering strong margins for franchise partners investing in specialist detailing.

Franchise Onboarding — Cardiac Diabetic Tablets

1. Contact us: +91-8729000609 | enquiry.saturn@gmail.com
2. Choose cardiac-diabetic SKUs from our full catalogue
3. Submit Drug License (Schedule H) and GST documents
4. Confirm territory and sign franchise agreement
5. Receive products and cardiology/diabetology promotional kit

Saturn Formulations' Cardiac Diabetic Tablet franchise offers the most stable, predictable, and high-value pharmaceutical business opportunity in India's chronic disease management market. Call +91-8729000609 today to get started.